StockMarketWire.com - Biotherapeutics company PureTech Health welcomed news that founded entity Alivio Therapeutics had awarded $3.3 million from US Department of Defense to advance a potential treatment for inflammatory bowel disease.
The funds would support Alivio's pre-clinical research and development activities to potentially enable the filing of an investigational new drug application for the treatment, called ALV-304.
'Alivio's inflammation-targeting, disease immunomodulation approach involves selectively restoring immune homeostasis at inflamed sites in the body, while having minimal impact on the rest of the body's immune system,' PureTech Health said.
At 1:04pm: [LON:PRTC] Puretech Health PLC share price was -5p at 249.5p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.